Publication at Faculty of Medicine in Hradec Králové |
2021
Abstract
The fixed combination of insulin degludec and insulin aspart (IDegAsp) is a mixture of long-acting basal insulin and bolus that overcomes the disadvantages of premixed insulins. It has a rapid onset of action that ensures coverage of postprandial insulin requirements, whereas the basal component has a flat and stable glucose-lowering profile providing continuous coverage of basal insulin requirements.
In clinical trials, the efficacy of IDegAsp was at least comparable to other insulin regimens and was generally associated with a lower risk of hypoglycaemia and a reduction in total insulin dose. Other advantages od IDegAsp over premixed insulins include ease od administration and flexibility of administration with meals.